Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

205.74 +1.54 (+0.75%)
Streaming Delayed Price Updated: 1:01 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
From AstraZeneca
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
From AstraZeneca
Via Business Wire
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
As of February 11, 2026, the corporate landscape is undergoing its most significant transformation in half a decade. After two years of high interest rates and regulatory gridlock that chilled the... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British... 
Via Finterra
Topics Artificial Intelligence Economy Fraud
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
AstraZeneca results: FY and Q4 2025
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
OAK Family Advisors Sells $4 Million of NICE Stock ↗
This software firm delivers AI-driven cloud platforms for enterprise customer engagement and compliance across global markets. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
From AstraZeneca
Via Business Wire
News headline image
US Trade Deficit Widens to -$56.8 Billion: A Surprise Drag on GDP Amid AI Infrastructure Surge
The U.S. economy faced a sobering reality check last week as the Bureau of Economic Analysis (BEA) released a trade report on January 29, 2026, revealing a deficit that widened far beyond initial... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.